The Middle East point of care molecular diagnostics market size was valued at USD 273.5 million in 2024 and is projected to reach USD 463.0 million by 2033, growing at a CAGR of 6.13% from 2025 to 2033. The Middle East and Africa (MEA) region encompasses countries with both advanced and emerging healthcare systems, offering a diverse landscape for point-of-care (POC) molecular diagnostics. Well-established healthcare markets, such as Saudi Arabia and the UAE, provide streamlined regulatory pathways, robust logistics, and advanced laboratory networks that support market entry and expansion.
Historically, the region has faced significant challenges with communicable diseases such as malaria and typhoid, and events like the Middle East Respiratory Syndrome (MERS) outbreak in 2015 heightened awareness of the need for rapid molecular diagnostics. The COVID-19 pandemic further accelerated adoption, as the Middle East saw an exponential rise in confirmed cases during early 2020, driving demand for portable and near-patient testing technologies.
In Saudi Arabia, government-led Vision 2030 initiatives emphasize localized manufacturing of molecular diagnostics and expanding public-private partnerships, creating a favorable market for POC platforms in both hospital and community health settings. The UAE is emerging as a regional innovation hub, with AI-enabled diagnostic platforms and ultra-rapid molecular testing solutions developed domestically, such as paper-based devices delivering results in under 10 minutes. Kuwait continues to invest in upgrading laboratory networks, with a growing share of testing shifting toward decentralized formats to improve patient turnaround times. Qatar is channeling resources into early disease detection programs, integrating POC molecular systems into primary care to address chronic and infectious disease burdens. Oman is adopting molecular point-of-care solutions in both urban and rural clinics, driven by national programs targeting respiratory infections, tuberculosis, and other high-prevalence conditions. Collectively, these developments position the Middle East as a rapidly advancing market for point-of-care molecular diagnostics, with strong governmental support and a growing appetite for cutting-edge healthcare technologies.
The UAE is witnessing a rise in the adoption of POC testing due to an increase in government initiatives aimed at the promotion of regular screening activities for cancer and other chronic diseases. For instance, the Ministry of Health and Prevention in the UAE regularly holds breast cancer screening programs, while the Department of Health-Abu Dhabi recommends & encourages frequent screening. Furthermore, the Ministry of Health & Prevention has launched several programs, such as the National Strategy for Fighting Diabetes, for reducing diabetes prevalence in the country.
This product will be delivered within 1-3 business days.
Historically, the region has faced significant challenges with communicable diseases such as malaria and typhoid, and events like the Middle East Respiratory Syndrome (MERS) outbreak in 2015 heightened awareness of the need for rapid molecular diagnostics. The COVID-19 pandemic further accelerated adoption, as the Middle East saw an exponential rise in confirmed cases during early 2020, driving demand for portable and near-patient testing technologies.
Target Disease Prevalence
Governments and private healthcare providers in MEA are strategically investing in infrastructure expansion, from upgrading tertiary hospitals to increasing the number of community-based clinics. These initiatives align with the integration of advanced POC molecular testing platforms capable of delivering fast and accurate results without reliance on centralized laboratories. Economic growth in several Gulf countries, including the UAE, Kuwait, and Qatar, is fueling higher healthcare spending, enabling the adoption of premium diagnostics for infectious diseases, chronic conditions, and sexually transmitted infections (STIs). Moreover, increasing patient awareness, higher purchasing power, and the shift toward preventive and personalized healthcare are expected to sustain market growth in the forecasted period.In Saudi Arabia, government-led Vision 2030 initiatives emphasize localized manufacturing of molecular diagnostics and expanding public-private partnerships, creating a favorable market for POC platforms in both hospital and community health settings. The UAE is emerging as a regional innovation hub, with AI-enabled diagnostic platforms and ultra-rapid molecular testing solutions developed domestically, such as paper-based devices delivering results in under 10 minutes. Kuwait continues to invest in upgrading laboratory networks, with a growing share of testing shifting toward decentralized formats to improve patient turnaround times. Qatar is channeling resources into early disease detection programs, integrating POC molecular systems into primary care to address chronic and infectious disease burdens. Oman is adopting molecular point-of-care solutions in both urban and rural clinics, driven by national programs targeting respiratory infections, tuberculosis, and other high-prevalence conditions. Collectively, these developments position the Middle East as a rapidly advancing market for point-of-care molecular diagnostics, with strong governmental support and a growing appetite for cutting-edge healthcare technologies.
The UAE is witnessing a rise in the adoption of POC testing due to an increase in government initiatives aimed at the promotion of regular screening activities for cancer and other chronic diseases. For instance, the Ministry of Health and Prevention in the UAE regularly holds breast cancer screening programs, while the Department of Health-Abu Dhabi recommends & encourages frequent screening. Furthermore, the Ministry of Health & Prevention has launched several programs, such as the National Strategy for Fighting Diabetes, for reducing diabetes prevalence in the country.
Middle East Point of Care Molecular Diagnostics Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East point-of-care molecular diagnostics market report on the basis of application, technology, test location, end-use, and region:Technology Outlook (Revenue, USD Million, 2021-2033)
- PCR-based
- Genetic Sequencing-based
- Hybridization-based
- Microarray-based
Application Type Outlook (Revenue, USD Million, 2021-2033)
- Infectious Diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Other Applications
Test Location Outlook (Revenue, USD Million, 2021-2033)
- OTC
- POC
End-use Outlook (Revenue, USD Million, 2021-2033)
- Decentralized Labs
- Hospitals
- Home-care
- Assisted Living Healthcare Facilities
- Others
Country Outlook (Revenue, USD Million, 2021-2033)
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Technology Business Analysis
Chapter 5. Application Business Analysis
Chapter 6. Test Location Business Analysis
Chapter 7. End Use Business Analysis
Chapter 8. Regional Business Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East Point of Care Molecular Diagnostics market report include:- F. Hoffmann-La Roche AG
- Abbott
- QIAGEN
- Bayer AG
- Nova Biomedical
- Danaher
- Nipro Diagnostics
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- bioMérieux
- OraSure Technologies
- Abaxis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 273.5 Million |
| Forecasted Market Value ( USD | $ 463.01 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 12 |
